Cingulate Inc. Share Price
CINGCingulate Inc. Stock Performance
Open $4.63 | Prev. Close $4.63 | Circuit Range N/A |
Day Range $4.52 - $4.71 | Year Range $3.23 - $11.78 | Volume 2,530 |
Average Traded $4.60 |
Cingulate Inc. Share Price Chart
About Cingulate Inc.
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Cingulate Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
19-May-26 | $4.38 | $4.36 | -2.46% |
18-May-26 | $4.79 | $4.47 | -2.83% |
15-May-26 | $4.31 | $4.60 | +3.95% |
14-May-26 | $4.53 | $4.42 | -9.69% |
13-May-26 | $4.84 | $4.90 | +2.30% |
12-May-26 | $4.91 | $4.79 | -2.84% |
11-May-26 | $5.05 | $4.93 | -4.46% |